全文获取类型
收费全文 | 194604篇 |
免费 | 2140篇 |
国内免费 | 88篇 |
专业分类
耳鼻咽喉 | 1224篇 |
儿科学 | 7095篇 |
妇产科学 | 3248篇 |
基础医学 | 18880篇 |
口腔科学 | 2317篇 |
临床医学 | 14220篇 |
内科学 | 35043篇 |
皮肤病学 | 1056篇 |
神经病学 | 18513篇 |
特种医学 | 9791篇 |
外科学 | 31843篇 |
综合类 | 2433篇 |
一般理论 | 7篇 |
预防医学 | 19270篇 |
眼科学 | 2855篇 |
药学 | 10746篇 |
中国医学 | 645篇 |
肿瘤学 | 17646篇 |
出版年
2023年 | 152篇 |
2022年 | 172篇 |
2021年 | 406篇 |
2020年 | 311篇 |
2019年 | 435篇 |
2018年 | 22346篇 |
2017年 | 17781篇 |
2016年 | 19889篇 |
2015年 | 1410篇 |
2014年 | 1481篇 |
2013年 | 1846篇 |
2012年 | 8301篇 |
2011年 | 22235篇 |
2010年 | 19532篇 |
2009年 | 12246篇 |
2008年 | 20587篇 |
2007年 | 22847篇 |
2006年 | 1737篇 |
2005年 | 3326篇 |
2004年 | 4376篇 |
2003年 | 5328篇 |
2002年 | 3423篇 |
2001年 | 498篇 |
2000年 | 586篇 |
1999年 | 385篇 |
1998年 | 412篇 |
1997年 | 413篇 |
1996年 | 239篇 |
1995年 | 257篇 |
1994年 | 260篇 |
1993年 | 208篇 |
1992年 | 200篇 |
1991年 | 235篇 |
1990年 | 266篇 |
1989年 | 204篇 |
1988年 | 178篇 |
1987年 | 160篇 |
1986年 | 161篇 |
1985年 | 158篇 |
1984年 | 115篇 |
1983年 | 131篇 |
1982年 | 114篇 |
1981年 | 94篇 |
1980年 | 106篇 |
1979年 | 88篇 |
1978年 | 95篇 |
1977年 | 72篇 |
1976年 | 63篇 |
1975年 | 74篇 |
1938年 | 63篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Beata Gawdis-Wojnarska Marek Brzosko Jacek Fliciński Krzysztof Marlicz Teresa Starzyńska Rodney J Scott Jan Lubiński 《Hereditary cancer in clinical practice》2004,2(2):65-68
Gastric cancer is the second most frequently diagnosed malignancy worldwide and therefore represents a significant healthcare burden. Environmental and genetic factors are involved in the development of gastric cancer. To date only one clear genetic predisposition has been identified involving mutations in the E-cadherin gene. The disease phenotype in patients harbouring E-cadherin mutations appears to be specifically related to diffuse gastric cancer. Little is known genetically about the other forms of gastric cancer. Since there is a growing awareness about the necessity of early intervention criteria have been developed that aid the identification of hereditary forms of gastric cancer. The aim of the current study was to identify minimal inclusion criteria so that nuclear pedigree families can be provided with risk assessment and/or genetic testing.The results reveal that inclusion features described herein such as (a) gastric cancer diagnosed before 46 years of age; (b) two gastric cancers among first degree relatives diagnosed over the age of 50 are useful in identifying suspected hereditary gastric cancer patients. 相似文献
992.
993.
994.
995.
996.
997.
Mitch Dowsett 《Breast cancer research and treatment》2004,87(1):11-18
cDNA arrays and proteomic analyses have allowed the rapid identification of specific genes and proteins implicated in multiple
tumor types. These molecules must then be validated as clinically relevant prognostic and predictive markers, and this translational
research is best conducted in the context of clinical trials. Outcomes data and clinical specimens collected in the ‘Arimidex’,
Tamoxifen, Alone or in Combination (ATAC) study, for example, can now be used to compare the expression of biomarkers with
clinical outcomes. In this study, adjuvant tamoxifen and anastrozole (‘Arimidex’) were compared alone and in combination in
more than 9000 women with breast cancer. Anastrozole was found to be superior to tamoxifen in terms of disease-free survival,
time to recurrence, and reduction in the incidence of contralateral tumors. Importantly, tissue specimens from surgical excision,
local relapse, and contralateral breast cancer were collected and paraffin-embedded for storage. In the TA01 (TransATAC) program,
these specimens will be studied (after obtaining patient consent) using tissue microarrays; tissue biopsy cores 0.6 mm in
diameter will be removed from donor blocks and placed on recipient blocks, which will be sectioned to allow the simultaneous
analysis of the same samples for multiple biomarkers. These analyses can help determine differential benefits of treatment
with anastrozole or tamoxifen, depending on the expression of particular biomarkers in tumor cells. This research also should
clarify de novo and acquired resistance mechanisms, and the validation of relevant molecular pathways could guide the development of new
drugs. Ultimately, the TA01 program has the potential to favorably impact treatment choices for breast cancer.
This revised version was published online in August 2006 with corrections to the Cover Date. 相似文献
998.
Objective: To study the gene polymorphisms of GSTT1 and GSTM1 in nasopharyngeal carcinoma (NPC) patients and controls in an
incidental area to evaluate the relationship between specific genotype and genotype combinations of these polymorphisms with
the risk of NPC. Methods: Cases and controls all came from the Southwestern Guangxi. DNAs were extracted from their WBC. PCR
technique was used to calculate the deletion rate of the two detoxific enzyme genes. Results: In this high risk area of NPC,
the residents had high level deletion rates of 47.4% (64/135) Ml and T1 40.7% (55/135). The deletion rates were even higher
in NPC patients, 61.5% (56/91) for Ml and 59.3% (54/91) for T1 respectively. There were statistical significances compared
with control,P<0.05 andP<0.01 for Ml and T1 respectively. The difference was more significant in terms of combined Ml and T1 deletion between patients
and controlsx
2=12.533,P=0.002. Conclusion: The combined deletion of detoxific enzyme genes GSTM1 and GSTT1 may be an important genetic susceptible
factor for NPC in Guangxi.
Biography: DENG Zhuo-lin (1929-), male, professor of pathology, Guangxi Medical University, majors in tumor pathology. E-mail :zhuolin@hotmail.com 相似文献
999.
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. 总被引:4,自引:0,他引:4
Firouzeh Korangy Lars A Ormandy J?rg S Bleck Jürgen Klempnauer Ludwig Wilkens Michael P Manns Tim F Greten 《Clinical cancer research》2004,10(13):4332-4341
PURPOSE: Hepatocellular carcinoma (HCC) is the fifth most common cancer around the world. Although several therapeutic approaches for treatment of HCC are available, survival rates for HCC patients are still very poor because of inefficient treatment options. For HCC, as well as other tumors, antigen-specific immunotherapy remains a viable approach that is dependent on the definition of tumor-associated antigens. NY-ESO-1, a member of the cancer testis antigen family, is one possible candidate for a tumor-specific antigen in HCC. The aim of this study was to show the relevance of NY-ESO-1 in hepatocellular carcinoma. EXPERIMENTAL DESIGN: Sera samples from 189 HCC patients were analyzed for NY-ESO-1-specific antibodies. Forty-nine HCC patients were screened for NY-ESO-1 mRNA expression in HCC tissue. Selected patients were followed for up to 3 years to correlate their immune response with their clinical course of events. NY-ESO-1-specific CD4+ and CD8+ T-cell responses from NY-ESO-1 seropositive patients were analyzed and a NY-ESO-1+ specific cytotoxic T-cell line was generated. RESULTS: Twelve of 49 analyzed tumor samples expressed NY-ESO-1 mRNA and 23 of 189 patients showed NY-ESO-1-specific antibody responses. These humoral immune responses were accompanied by NY-ESO-1-specific functional CD4+ and CD8+ T-cell responses. Finally, NY-ESO-1 humoral responses were dependent on the presence of NY-ESO-1-expressing tumors. CONCLUSIONS: This is the first report of a spontaneous immune response in HCC patients to a known tumor-specific antigen, NY-ESO-1 protein. Our data favor the possibility of immunotherapeutic strategies for the treatment of HCC. 相似文献
1000.
Background Duodenogastric reflux is known to cause an increased frequency of cancer in the glandular portion of the stomach in rats. Furthermore, it is debated whether inhibition of gastric acid secretion may promote gastric carcinogenesis. In the present study we examined the combined effect of gastroduodenal reflux and acid inhibition with respect to the development of gastric carcinoma in the rat.Methods Following the construction of a gastrojejunostomy in male Wistar rats, half of them were given the proton pump inhibitor lanzoprazole for 1 year. The rats were then killed and the pH in the stomach and gastrin in blood were measured. The stomach was examined macroscopically as well as histologically.Results Gastrin levels at autopsy were significantly increased in treated rats compared to the control group, confirming an effect of lanzoprazole on gastric acid secretion. Body weight was significantly reduced in the treated rats. Thirty of 79 rats developed gastric cancer, and they were all adenocarcinomas of the Lauren intestinal type. Gastric cancers occurred significantly more often in lanzoprazole-treated rats (50%) compared with controls (27%).Conclusion Lanzoprazole given orally enhances the carcinogenic effect of duodenogastric reflux in rats. 相似文献